Neuronal glucose metabolism and schizophrenia: therapeutic prospects?

References

• Rice DR The economic impact of schizophrenia. J. Clin. PFchiatry60\(Suppl. 1), 4–6 (1999).
   Google Scholar
• Gillberg C, Wahlstrom J, Forsman A, Hellgren L, Gillberg IC. Teenage psychoses– epidemiology, classification and reduced optimality in the pre-, peri- and neonatal periods. J. Child Psychol. Psychiatry 27, 87–98 (1986).
   Google Scholar
• Stephenson J. Children with mental problems not getting the care they need. JAMA 284, 2043–2044 (2000).
   PubMedGoogle Scholar
• Kelleher KJ, McInerny TK, Gardner WP, Childs GE, Wasserman RC. Increasing identification of psychosocial problems: 1979–1996. Pediatrics 105, 1313–1321 (2000).
   Google Scholar
• Jensen PS, Vitiello B, Leonard H, Laughren TP. Design and methodology issues for clinical treatment trials in children and adolescents. Psychopharmacol. Bull. 30, 3–8 (1994).
   PubMedGoogle Scholar
• Findling RL, Schulz C, Reed MD, Blumer, JL. The antipsychotics: a pediatric perspective. Child Adoles. Psychopharmacol.45, 1205–1232 (1998).
   Google Scholar
• • Excellent summary of clinical trials in children and adolescents.
   Google Scholar
• Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 283, 1025–1030 (2000).
   PubMed Web of Science ®Google Scholar
• •• Highlights the problems of prescribing psychotropic drugs to young children.
   Google Scholar
• Armenteros JL, Whitaker AH, Welikson M, Stedge DJ, Gorman J. Risperidone in adolescents with schizophrenia: an open pilot study. J. Am. Acad. Child Adolesc. Psychiatry 36, 694–700 (1997).
   Google Scholar
• Toren P, Laor N, Weizman A. Use of atypical neuroleptics in child and adolescent psychiatry. J. Clin. Psychiatry 59, 644–656 (1998).
   Google Scholar
• • Excellent summary of clinical trials in children and adolescents.
   Google Scholar
• Lewis R. Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability and differential sensitivity to extrapyramidal symptoms. Can. J. Psychiatry 43, 596–604 (1998).
   PubMed Web of Science ®Google Scholar
• • Excellent summary of clinical trials in children and adolescents.
   Google Scholar
• Vitiello B. Pediatric psychopharmacology and the interaction between drugs and the developing brain. Can. J. Psychiatry 43, 582–584 (1998).
   PubMed Web of Science ®Google Scholar
• Coyle JT. Psychotropic drug use in very young children. /AIWA 283,1059–1060 (2000).
   PubMed Web of Science ®Google Scholar
• Wyatt RJ. Early intervention for schizophrenia: can the course of the illness be altered? Biol. Fiychiatry 38,1–3 (1995).
   PubMed Web of Science ®Google Scholar
• Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence?' Psychiatry Res. 17, 319–334 (1982).
   Google Scholar
• •Seminal paper on the neurodevelopmental theory of schizophrenia.
   Google Scholar
• Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Adh. Gen. Psychiatry 44, 660–669 (1987).
   PubMed Web of Science ®Google Scholar
• •Seminal paper on the neurodevelopmental theory of schizophrenia.
   Google Scholar
• Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol. Psychiati y45, 17–25 (2000).
   Google Scholar
• McGlashan TH, Hoffman RE. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch. Gen Psychiatry 57,637–648 (2000).
   PubMed Web of Science ®Google Scholar
• Lewis DA, Levitt P Schizophrenia as a disorder of neurodevelopment. Ann. Rev Neurosci 25,409–432 (2002).
   PubMed Web of Science ®Google Scholar
• ••Excellent review of theories of the etiologyof schizophrenia.
   Google Scholar
• Giedd JN, Jeffries NO, Blumenthal J etal. Childhood-onset schizophrenia: progressive brain changes during adolescence. Biol. Psychiatry46,892–898 (1999).
   Google Scholar
• Thompson PM, Vidal C, Giedd JN et al Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Ffon Natl Acad. Sci. USA 98,11650–11655 (2001).
   PubMed Web of Science ®Google Scholar
• •Critical paper showing loss of gray matter in early-onset schizophrenia in children.
   Google Scholar
• Sokoloff L. Circulation and energy metabolism of the brain. In: Basic Neurochemistry Siegel GJ, Albers RW, Katzman R, Agranoff BW (Eds), Little, Brown and Company, Boston, MA, USA, 388–413 (1976).
   Google Scholar
• Blass JR Glucose/mitochondria in neurological conditions. Int. Rev Neurobiol 51,326–376 (2002).
   Google Scholar
• Newcomer JW, Craft S, Fucetola R et al Glucose-induced increase in memory performance in patients with schizophrenia. Schizophr. Bull 25,321–335 (1999).
   PubMed Web of Science ®Google Scholar
• Dwyer DS, Bradley RJ, Kablinger AS, Freeman AM III. Glucose metabolism in relation to schizophrenia and antipsychotic drugs. Ann. Clin. PTchiatry13, 103–113 (2001).
   Google Scholar
• •Reviews numerous connections between schizophrenia and glucose metabolism.
   Google Scholar
• Moises HW, Zoega T, Gottesman II. The glial growth factor deficiency and synaptic destabilization hypothesis of schizophrenia. BMC PTchiatry2,8–21 (2002).
   Google Scholar
• Hajduch E, Litherland GJ, Hundal HS. Protein kinase B (PKB/Akt) — a key regulator of glucose transport? FEBS Lett. 492,199–203 (2001).
   Google Scholar
• Baquer NZ, Hothersall JS, McLean P. Function and regulation of the pentose phosphate pathway in brain. CI.117: Topics Cell Reg. 29,265-289 (1988).
   Google Scholar
• Tian W-N, Braunstein LD, Apse K, Pang J, Stanton RC. Importance of glucose-6-phosphate dehydrogenase activity in cell death. AIR I Physiol 276, C1121—C1131 (1999).
   Google Scholar
• Seeman P Atypical antipsychotics: mechanism of action. Can. J. Psychiatiy47, 27–38 (2002).
   PubMedGoogle Scholar
• Birmaher B, Baker R, Kapur S, Quintana H, Ganguli R. Clozapine for the treatment of adolescents with schizophrenia. J. Am. Acad. Child Adolesc. Fiychiatry31, 160–164 (1992).
   PubMedGoogle Scholar
• Chalasani L, Kant R, Chengappa KN. Clozapine impact on clinical outcomes and aggression in severely ill adolescents with childhood-onset schizophrenia. Can. J. FiychMtry46, 965–968 (2001).
   Google Scholar
• Kumra S, Frazier JA, Jacobsen LK et al Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch. Gen PTchiatry53, 1090–1097 (1996).
   PubMed Web of Science ®Google Scholar
• Turetz M, Mozes T, Toren P et al An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia. Br. J. FiychMtry170, 507–510 (1997).
   PubMed Web of Science ®Google Scholar
• Meltzer HY, McGurk SR. The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25,233–255 (1999).
   PubMed Web of Science ®Google Scholar
• •Very useful summary of clinical studies on the cognitive effects of antipsychotic drugs.
   Google Scholar
• Purdon SE, Labelle A, Boulay L. Neuropsychological change in schizophrenia after 6weeks of clozapine. Schizophr Res. 48,57-67 (2001).
   Google Scholar
• Potkin SG, Fleming K, Jin Y, Gulasekaram B. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. j Clin. Psychopharmacol 21,479–483 (2001).
   PubMed Web of Science ®Google Scholar
• Bilder RM, Goldman RS, Volavka J etal Neurocognitive effects of clozapine, olanzapine, risperidone and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Amj Psychiatry 159,1018–1028 (2002).
   PubMed Web of Science ®Google Scholar
• Goldberg TE, Weinberger DR. Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. J. Clin. Psychiatry57\(Suppl. 9), 62–65 (1996).
   Google Scholar
• Hoff AL, Faustman WO, Wieneke M et al. The effects of clozapine on symptom reduction, neurocognitive function and clinical management in treatment refractory state hospital schizophrenic in-patients. Neuropsychopharmacology15, 361–369 (1996).
   PubMed Web of Science ®Google Scholar
• Dwyer DS, Pinkofsky HB, Liu Y, Bradley RJ. Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC12 cells. Pug. Neum-Psychophatmacol Biol. Bychiatry23,69–80 (1999) .
   Google Scholar
• Dwyer DS, Liu Y, Bradley RJ. Dopamine receptor antagonists modulate glucose uptake in rat pheochromocytoma (PC12) cells. Neurosci. Lett. 274,151-154 (1999).
   Google Scholar
• Ardizzone TD, Bradley RJ, Freeman AM III, Dwyer DS. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine and structural analogs of clozapine. Brain Res. 923,82–90 (2001).
   PubMedGoogle Scholar
• Hagg S, Joelsson L, Mjomdal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J. Clin. Psychiatry 59,294–299 (1998).
   PubMed Web of Science ®Google Scholar
• Henderson DC, Cagliero E, Gray C eta]. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: A five-year naturalistic study. Am. .1. Rychiatry157, 975–981 (2000).
   Google Scholar
• •Essential paper for those interested in the link between antipsychotic drugs and diabetes.
   Google Scholar
• Donohoe D, Dwyer DS. Induction of hyperglycemia in mice by administration of antipsychotic drugs. FASEBJ 16, A568 (2002).
   Google Scholar
• Dwyer DS, Ardizzone TD, Bradley RJ. Psychoactive drugs affect glucose transport and the regulation of glucose metabolism. Int. Rev. Neurobiol 51,503–530 (2002).
   Google Scholar
• Dwyer DS, Lu X-H, Bradley RJ. Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism. Under review (2002).
   Google Scholar
• Quintana H, Keshavan M. Case study: Risperidone in children and adolescents with schizophrenia. j Am Acad. Child Adolesc. PTchiatry34, 1292–1296 (1995).
   PubMed Web of Science ®Google Scholar
• Grcevich SJ, Findling RL, Rowane WA, Friedman L, Schulz SC. Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. J. Child Adolesc. PTchophalmacol. 6,251-257 (1996).
   Google Scholar
• Simeon J, Milin R, Walker S. A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders. Prog. Neuropsychopharmacol Biol. Fiychiatry26, 267–275 (2002).
   Google Scholar
• Cannon TD, Huttunen MO, Dahlstrom M, Larmo I, Rasanen P, Juriloo A. Antipsychotic drug treatment in the prodromal phase of schizophrenia. Am. j PTchiatry159, 1230–1232 (2002).
   PubMed Web of Science ®Google Scholar
• •Provides first solid attempt to treat prodromal schizophrenia.
   Google Scholar
• Sharma T, Mockler D. The cognitive efficacy of atypical antipsychotics in schizophrenia. j Clin. Psychopharmacol 18(2 Suppl. 1), 12S-19S (1998).
   Google Scholar
• Green MF, Marder SR, Glynn SM etal The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol. Fiychiatry 51,972–978 (2002).
   PubMed Web of Science ®Google Scholar
• ••Critical analysis of the neurocognitiveeffects of the antipsychotic drugs.
   Google Scholar
• Carpenter WT Jr, Gold JM. Another view of therapy for cognition in schizophrenia. Biol. Psychiatry51, 969–971 (2002).
   PubMedGoogle Scholar
• ••Critical analysis of the neurocognitiveeffects of the antipsychotic drugs.
   Google Scholar
• Frazier JA, Biederman J, Tohen M etal A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J. Child Adolesc. Fiychophatmacolll, 239–250 (2001).
   Google Scholar
• Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. j Arm Acad. Child Adolesc. PTchiatry40, 887–894 (2001).
   Google Scholar
• Malek-Ahmadi P, Simonds JE Olanzapine for autistic disorder with hyperactivity. J. Am. Acad. Child Adolesc. Psychiatry37, 902 (1998).
   PubMed Web of Science ®Google Scholar
• Kemner C, Willemsen-Swinkels SH, De Jonge M, Tuynman-Qua H, Van Engeland H. Open-label study of olanzapine in children with pervasive developmental disorder. j Clin. PTchophalmacol 22,455–460 (2002).
   PubMed Web of Science ®Google Scholar
• Kumra S, Jacobsen LK, Lenane M eta]. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. j Am. Acad. Child Adolesc. Psychiatry 37, 377–385 (1998).
   Google Scholar
• Mandoki M. Olanzapine in the treatment of early onset schizophrenia in children and adolescents. Biol. PTchiatry41, 22S (1997).
   Google Scholar
• Haapsalo-Pesu KM, Saarijarvi S. Olanzapine induces remarkable weight gain in adolescent patients. Eur. Child Adolesc. Psychiatry 10,205–208 (2001).
   PubMedGoogle Scholar
• Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C Jr, Tollefson GD. Olanzapine versus haloperidol treatment in first-episode psychosis. Am. J. Psychiatry 156,79–87 (1999).
   PubMed Web of Science ®Google Scholar
• Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res. 48,17–28 (2001).
   PubMed Web of Science ®Google Scholar
• Purdon SE, Jones BDW, Stip E etal Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone or haloperidol. Arch. Gen. Psychiatry 57, 249–258 (2000).
   Google Scholar
• Smith RC, Infante M, Singh A, Khandat A. The effect of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. int. J. Neuropsychopharmacol 4,239–250 (2001).
   PubMed Web of Science ®Google Scholar
• Grove VE Jr, Quintanilla J, DeVaney GT. Improvement in Huntington's disease with olanzapine and valproate. N Engl. J. Med. 343,973–974 (2000).
   Google Scholar
• Agarwal V, Kumar P Olanzapine in the treatment of tardive dyskinesia. I Clin. PTchiatry 62,298–299 (2001).
   PubMedGoogle Scholar
• Lu X-H, Bradley RJ, Dwyer DS. Neuroenhancing effects of olanzapine are mediated via the PI3K/Akt pathway and glucose transport regulation. Submitted for publication (2002).
   Google Scholar
• Lawlor MA, Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?I Cell Sci. 114,2903–2910 (2001).
   Google Scholar
• Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am. J. Psychiatry 159,655–657 (2002).
   Google Scholar
• Szigethy E, Brent S, Findling RL. Quetiapine for refractory schizophrenia. J. Aim Acad. Child Adolesc. Psychiatry 37, 1127–1128 (1998).
   PubMedGoogle Scholar
• Healy E, Subotsky F, Pipe R. Quetiapine in adolescent psychosis. J. Am. Acad. Child Adolesc Psychiatry 38,1329 (1999).
   PubMedGoogle Scholar
• McConville BJ, Arvanitis LA, Thyrum PT eta]. Pharmacokinetics, tolerability and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. I an. Psychiatry 61,252–260 (2000).
   Google Scholar
• Shaw JA, Lewis JE, Pascal S eta]. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J. Child Adolesc PTchophalmacol 11,415–424 (2001).
   Google Scholar
• Fleming K, Thyrum P, Yeh C, Vargu DL, Potkin SG. Cognitive improvements in psychotic subjects treated with `Seroquel' (quetiapine fumarate): an exploratory study. J. Clin. PTchophatmacol 21,527–529 (2001).
   Google Scholar
• Purdon SE, Malla A, Labelle A, Lit W Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. I Psychiatry Neurosci. 26,137–149 (2001).
   PubMed Web of Science ®Google Scholar
• Velligan DI, Newcomer J, Pultz J et al Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res. 53,239–248 (2002).
   Google Scholar
• Sallee FR, Kurlan R, Goetz CG etal Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J. Am. Acad. Child Adolesc. PTchiatry 39,292–299 (2000).
   PubMed Web of Science ®Google Scholar
• Patel NC, Sierk P, Dorson PG, Crismon ML. Experience with ziprasidone. jAm Acad. Child Adolesc Bychiatry41, 495 (2002).
   PubMedGoogle Scholar
• Goodnick PJ. Ziprasidone: profile on safety. Expert Opinion Pharmacother. 2, 1655–1662 (2001).
   PubMedGoogle Scholar
• Burris KD, Molski TF, Xu C etal. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol Exp. Ther 302,381–389 (2002).
   Google Scholar
• •Discusses an interesting new antipsychotic drug.
   Google Scholar
• Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1 A receptor. Eur Pharmacol 441,137–140 (2002).
   PubMed Web of Science ®Google Scholar
• Kane JM, Carson WH, Saha AR et al Efficacy and safety of aripriprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Clin. Bychiatry63, 763–771 (2002).
   PubMedGoogle Scholar
• Newcomer JW, Haupt DW, Fucetola R et al Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Aith. Gen. Psychiatry 59, 337–345 (2002).
   PubMed Web of Science ®Google Scholar
• •Excellent review of abnormalities in glucose metabolism induced by antipsychotic drugs.
   Google Scholar
• Ratzoni G, Gothelf D, Brand-Gothelf A et al Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J. Am. Acad. Child Adolesc. PTchiatry41, 337–343 (2002).
   PubMed Web of Science ®Google Scholar
• Tsuang MT, Stone WS, Faraone SV. Towards the prevention of schizophrenia. P.Tchti y 48, 349–356 (2000).
   Google Scholar
• •Important overview of the field.
   Google Scholar
• Kan O, Baldwin S, Whetton A. Apoptosis is regulated by the rate of glucose transport in an interleukin-3-dependent cell line. j Exp. Med 180,917–923 (1994).
   Google Scholar
• Berridge MV, Tan AS. Interleukin-3 facilitates glucose transport in a myeloid cell line by regulating the affinity of the glucose transporter for glucose: involvement of protein phosphorylation in transporter activation. Biochem. J. 305, 843–851 (1995).
   Google Scholar
• Dwyer DS, Liu Y, Bradley RJ. An ethanol- sensitive variant of the PC12 neuronal cell line: sensitivity to ethanol is associated with increased cell adhesion and decreased glucose accumulation. J. Cell Physiol 178, 93–101 (1999).
   Google Scholar
• Moley KH, Mueclder MM. Glucose transport and apoptosis. Apoptosis 5,99–105 (2000).
   PubMed Web of Science ®Google Scholar
• Gupta A, Ho DY, Brooke S etal Neuroprotective effects of an adenoviral vector expressing the glucose transporter: a detailed description of the mediating cellular events. Brain Res. 908,49–57 (2001).
   PubMedGoogle Scholar
• Gold PE. Role of glucose in regulating the brain and cognition. Am. J. Clin. Nutt: 61(4 Suppl.), 987S-995S (1995).
   Google Scholar
• Korol DL. Enhancing cognitive function across the lifespan. Ann. NY Acad. Li. 959, 167–179 (2002).
   PubMed Web of Science ®Google Scholar
• Azari NP. Effects of glucose on memory processes in young adults. Bychophatmacology105,521–524 (1991).
   PubMed Web of Science ®Google Scholar
• Craft S, Asthana S, Schellenberg G eta]. Insulin effects on glucose metabolism, memory and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann. NY Acad. Sci. 903, 222–228 (2000).
   Google Scholar
• Bondy CA, Cheng CM. Insulin-like growth factor-1 promotes neuronal glucose utilization during brain development and repair processes. Int. Rev Neurobiol 51, 189–217 (2002).
   Google Scholar
• Bedwell JS, Keller B, Smith AK, Hamburger S, Kumra S, Rapoport JL. Why does postpsychotic IQ decline in childhood-onset schizophrenia? Am. J. Bychtry156, 1996–1997 (1999).
   PubMed Web of Science ®Google Scholar
• Cosway R, Byrne M, Clafferty R et al Neuropsychological change in young people at high risk for schizophrenia: results from the first two neuropsychological assessments of the Edinburgh High Risk Study. Psychol. Med. 30,1111–1121 (2000).
   PubMed Web of Science ®Google Scholar
• Rowley M, Bristow L, Hutson PH. Current and novel approaches to the drug treatment of schizophrenia. J. Med. Chem. 44,477–501 (2001).
   Google Scholar
• Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol. PTchiatry 45, 1–16 (1999).
   Google Scholar
• Dwyer DS, Vannucci SJ, Simpson IA. Expression, regulation and functional role of glucose transporters (GLUTs) in brain. Int. Rev Neurobiol 51,159–188 (2002).
   Google Scholar
• Gruetter R, Seaquist ER, Ugurbil K. A mathematical model of compartmentalized neurotransmitter metabolism in the human brain. A117. I Physiol 281, E100—E112 (2001).
   Google Scholar
• Magistretti PJ, Pellerin L, Rothman DL, Shulman RG. Energy on demand. Science 283,496–497 (1999).
   PubMed Web of Science ®Google Scholar
• Tamminga CA. Schizophrenia and glutamate transmission. Ctit. Rev Neumbiol 12,21–36 (1998).
   Google Scholar
• Paterson D, Nordberg A. Neuronal nicotinic receptors in the human brain. Frog. Neurobiol 61,75–111 (2000).
   Google Scholar
• Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am. Psychiatry155,1490–1501 (1998).
   Google Scholar
• de Leon J, Becona E, Gurpegui M, Gonzalez-Pinto A, Diaz FJ. The association between high nicotine dependence and severe mental illness may be consistent across countries. j Clin. Psychiatry 63, 812–816 (2002).
   Google Scholar
• Duelli R, Staudt R, Gruenwald F, Kuschinsky W Increase of glucose transporter densities (GLUT1 and GLUT3) during chronic administration of nicotine in rat brain. Bmin Res: 782,36–42 (1998).
   PubMedGoogle Scholar
• Boado RJ. Brain-derived peptides regulate the steady-state levels and increase stability of the blood-brain barrier GLUT1 glucose transporter mRNA. Neumsci. Lett. 197, 179–182 (1995).
   Google Scholar
• Cheng CM, Reinhardt RR, Lee W-H, Joncas G, Patel SC, Bondy CA. Insulin-like growth factor 1 regulates developing brain glucose metabolism. Proc. Natl Acad. Sci. USA 97,10236–10241 (2000).
   Google Scholar
• Panisset M, Gauthier S, Moessler H, Windisch M, The Cerebrolysin Study Group. Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent. Neural 7iansm. 109,1089-1104 (2002).
   Google Scholar
• Simpson IA, Chundu K, Davies-Hill T, Honer WG, Davies P. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann. New& 35,546–551 (1994).
   Google Scholar
• Heininger K. A unifying hypothesis of Alzheimer's disease. IV. Causation and sequence of events. Rev Neurosci 11, 213–328 (2000).
   PubMed Web of Science ®Google Scholar
• •Thought-provoking article.
   Google Scholar
• Cooper JR, Pincus JH. The role of thiamine in nervous tissue. Neurochem. Res. 4,223–239 (1979).
   PubMed Web of Science ®Google Scholar
• Iwata H, Yabushita Y, Doi T, Matsuda T Synthesis of thiamine triphosphate in rat brain in vivo. Neurochem. Res. 10,779–787 (1985).
   PubMedGoogle Scholar
• Feinberg JE The Wemicke-Korsakoff syndrome. Am. Fam. Physician 22,129–133 (1980).
   PubMedGoogle Scholar
• Sacks W, Esser AH, Feitel B, Abbott K. Acetazolamide and thiamine: an ancillary therapy for chronic mental illness. Psychiatry Res. 28,279–288 (1989).
   PubMedGoogle Scholar
• Chalecka-Franaszek E, Chuang D-M. Lithium activates the serineithreonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc. Natl Acad. Sci. USA 96, 8745–8750 (1999).
   Google Scholar
• Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. J. Neurochem. 75,1729–1734 (2000).
   Google Scholar
• Moore GJ, Bebchuk JM, Wilds TB, Chen G, Menji HK. Lithium-induced increase in human brain grey matter. Lancet 356, 1241–1242 (2000).
   Google Scholar
• •Very interesting paper.
   Google Scholar